Suppr超能文献

干扰素α治疗与甲状腺功能检查在丙型肝炎管理中的相互作用:一例报告

Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report.

作者信息

Gill Gurmit, Bajwa Hammad, Strouhal Peter, Buch Harit N

机构信息

Department of Endocrinology and Diabetes, New Cross Hospital, Wolverhampton, WV10 0QP, UK.

Department of Radiology, New Cross Hospital, Wolverhampton, WV10 0QP, UK.

出版信息

J Med Case Rep. 2016 Sep 15;10(1):253. doi: 10.1186/s13256-016-1028-y.

Abstract

BACKGROUND

Interferon alpha is a widely used therapeutic agent in the treatment of hepatitis C virus infection. Clinical thyroid disease is seen in nearly 15 % of patients receiving interferon alpha for hepatitis C virus infection. The mechanism of thyroid dysfunction with interferon alpha is either autoimmune or inflammatory. We report a case of young woman who developed biphasic thyroid dysfunction posing a diagnostic challenge, while receiving interferon alpha treatment for hepatitis C virus infection.

CASE PRESENTATION

A 29-year-old, Caucasian woman with type 1 diabetes and hepatitis C virus infection was referred with hyperthyroidism, while she was at 17 weeks of a planned 24-week course of interferon alpha therapy. A laboratory investigation revealed a thyroid stimulation hormone level of 0.005 mU/L (0.350-4.94), free thyroxine of 45.6 pmol/L (9.0-19.0) and free tri-iodothyronine of 12.6 pmol/L (2.6-5.7). She had a mild neutropenia and alanine aminotransferase at double the reference value. Her thyroid peroxidase antibody level was 497 ku/L (<5.6) and thyroid inhibitory factor 7 IU/L (>1.8 iu/l is positive). Thyroid scintigraphy with technetium99 scan confirmed a normal-sized thyroid gland with diffuse but normal overall uptake. A diagnosis of interferon alpha-triggered autoimmune hyperthyroidism as opposed to an inflammatory thyroiditis was made. She was offered radioactive iodine therapy, as thionamides were considered inappropriate in view of her liver disease and mild neutropenia. Due to our patient's personal circumstances, radioactive iodine therapy was delayed by 8 weeks and her thyrotoxic symptoms were controlled with beta-blockers alone. A repeat thyroid function test, 4 weeks post treatment with interferon alpha, indicated spontaneous conversion to hypothyroidism with a thyroid stimulation hormone level of 100 mU/L, free thyroxine of 5.2 pmol/L and free tri-iodothyronine of 1.7 pmol/L. She subsequently received levothyroxine for 4 months only and had remained euthyroid for the last 3 months without any treatment.

CONCLUSIONS

Initial investigations favored the autoimmune nature of hyperthyroidism but follow-up of the case, interestingly, was more consistent with inflammatory thyroiditis. We propose that this can be explained either on the basis of autoimmune subacute thyroiditis or a change in the nature of thyroid stimulation hormone receptor antibody production from stimulating-type to blocking-type antibodies, with disappearance of the latter on discontinuation of interferon alpha.

摘要

背景

干扰素α是治疗丙型肝炎病毒感染广泛使用的治疗药物。在接受干扰素α治疗丙型肝炎病毒感染的患者中,近15%出现临床甲状腺疾病。干扰素α导致甲状腺功能障碍的机制为自身免疫性或炎症性。我们报告1例年轻女性,在接受干扰素α治疗丙型肝炎病毒感染时出现双相甲状腺功能障碍,这给诊断带来了挑战。

病例介绍

一名29岁的患有1型糖尿病和丙型肝炎病毒感染的白人女性,在接受为期24周的干扰素α治疗的第17周时因甲状腺功能亢进前来就诊。实验室检查显示促甲状腺激素水平为0.005 mU/L(0.350 - 4.94),游离甲状腺素为45.6 pmol/L(9.0 - 19.0),游离三碘甲状腺原氨酸为12.6 pmol/L(2.6 - 5.7)。她有轻度中性粒细胞减少,丙氨酸转氨酶是参考值的两倍。她的甲状腺过氧化物酶抗体水平为497 ku/L(<5.6),甲状腺抑制因子为7 IU/L(>1.8 iu/l为阳性)。用锝99扫描进行甲状腺闪烁显像证实甲状腺大小正常,摄取弥漫但正常。诊断为干扰素α引发的自身免疫性甲状腺功能亢进,而非炎症性甲状腺炎。鉴于她的肝脏疾病和轻度中性粒细胞减少,认为硫代酰胺不合适,因此为她提供了放射性碘治疗。由于患者的个人情况,放射性碘治疗推迟了8周,仅用β受体阻滞剂控制了她的甲状腺毒症症状。在干扰素α治疗4周后复查甲状腺功能,结果显示自发转变为甲状腺功能减退,促甲状腺激素水平为100 mU/L,游离甲状腺素为5.2 pmol/L,游离三碘甲状腺原氨酸为1.7 pmol/L。随后她仅接受了4个月的左甲状腺素治疗,在过去3个月未接受任何治疗的情况下一直保持甲状腺功能正常。

结论

初步检查支持甲状腺功能亢进的自身免疫性质,但有趣的是,该病例的随访结果更符合炎症性甲状腺炎。我们认为这可以基于自身免疫性亚急性甲状腺炎来解释,或者基于甲状腺刺激激素受体抗体产生的性质从刺激性抗体转变为阻断性抗体来解释,后者在停用干扰素α后消失。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ca3/5025554/7b688ecbb49b/13256_2016_1028_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验